Three Gene Therapies, Moderna Metabolic Drug In Inaugural START Class; CBER Oversubscribes

Seven rare disease programs make up the first round of participants in the US FDA’s ‘Operation Warp Speed’-style program. Sponsors will benefit from ‘rapid, ad hoc’ communication with the agency.

start 2024 button
FDA to seven rare disease sponsors: Let's Go. • Source: Shutterstock

The US Food & Drug Administration’s inaugural class of applications for its START rare disease pilot program includes three early-stage gene therapy programs intended to treat pediatric diseases, including Rett syndrome (Neurogene), NGLY1 deficiency (Grace Science), and Canavan disease (Myrtelle).

The FDA announced the “Support for clinical Trials Advancing Rare disease Treatment” (START) pilot last fall as offering an “Operation...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Cell & Gene Therapies

More from Advanced Technologies